Abstract
The microvasculature of the human brain consists of approximately 400 miles of capillaries with a surface area of about 100 square feet (Pardridge, 1991). Because the capillary network in the brain is so extensive, Pardridge has suggested that “nearly every neuron is virtually perfused by its own microvessel” (Pardridge, 2002). Yet, despite this extensive surface area and the fact that the blood-brain barrier (BBB) is comprised of a cell monolayer having a thickness of only 200–300 nm, the impermeability of this barrier is widely acknowledged, and methods to circumvent it have been the subject of many reviews (Rapoport, 1976; Rapoport et al., 1979; Fenstermacher and Rapoport, 1984; Neuwelt, 1989; Pardridge, 1991, 1993, 2001; Bradbury, 1992; Drewes and Betz, 1993; Anderson, 1996).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small Je, Herrlinger U, Ourednik V, P. M. Black, Breakefield XO and Snyder EY. Neural Stem Cells Display Extensive Tropism for Pathology in Adult Brain: Evidence from Intracranial Gliomas. Proc Natl Acad Sci USA 2000; 97:12846–12851
Aggarwal SK, Gogu SR, Rangan SRS and Agrawal KC. Synthesis and Biological Evaluation of Prodrugs of Zidovudine. J Med Chem 1990; 33:1505–1510
Aghi M, Kramm CM, Chou TC, Breakefield XO and Chiocca EA. Synergistic Anticancer Effects of Ganciclovir/Thymidine Kinase and 5-Fluorocytosine/Cytosine Deaminase Gene Therapies. J Natl Cancer Inst 1998; 90:370–380
Al-Khalidi UAS and Chaglassian TH. The Species Distribution of Xanthine Oxidase. Biochem J 1965; 97:318–320
Altomare C, Carotti A, Cellamare S, Ferappi M, Cagiano R and Renna G. QSAR Analysis of Chemical and Serum-Catalyzed Hydrolysis of Phenyl Ester Prodrugs of Nipecotic Acid. Int J Pharm 1988; 48:91–102
Anderson BD. Prodrugs for Improved CNS Delivery. Adv Drug Deliv Rev 1996; 19:171–202
Anderson WR, Simpkins JW, Brewster ME and Bodor N. Evidence of the Reestablishment of Copulatory Behavior in Castrated Male Rats with a Brain-Enhanced Estradiol-Chemical Delivery System. Pharmacol Biochem Behav 1986; 27:265–271
Anderson BD, Wygant MB, Xiang T-X, Waugh WA and Stella V. Preformulation Solubility and Kinetic Studies of 2′,3′-Dideoxypurine Nucleosides: Potential Anti-AIDS Agents. Int J Pharm 1988; 45:27–37
Anderson BD, Hoesterey BL, Baker DC and Galinsky RE. Kinetics of DDI in Plasma, Brain, and CSF of Rats after Administration of DDI and an Ester Prodrug of DDI. Ann NY Acad Sci 1990a; 616:472–474
Anderson BD, Hoesterey BL, Baker DC and Galinsky RE. Uptake Kinetics of 2′,3′-Dideoxyinosine into Brain and Cerebrospinal Fluid of Rats: Intravenous Infusion Studies. J Pharmacol Exp Ther 1990b; 253:113–118
Anderson BD, Galinsky RE, Baker DC, Chi S-C, Hoesterey BL, Morgan ME, Murakami K and Mitsuya H. Approaches Toward the Optimization of CNS Uptake of Anti-AIDS Agents. J Control Release 1992; 19:219–230
Anderson BD, Morgan ME and Singhal D. Enhanced Oral Bioavailability of DDI after Administration of 6-CI-DDP, an Adenosine Deaminase-Activated Prodrug, to Chronically Catheterized Rats. Pharm Res 1995; 12:1126–1133
Apiwattanakul N, Sekine T, Chairoungdue A, Kanai Y, Nakajima N, Sophasan S and Endou H. Apiwattanakul N, Sekine T, Chairoungdue A, Kanai Y, Nakajima N, Sophasan S and Endou H. Transport Properties of Nonsteroidal Anti-Inflammatory Drugs by Organic Anion Transporter 1 Expressed in Xenopus Laevis Oocytes Mol Pharmacol 1999; 55:847–854
Badir K, Haj-Yehia A, Vree TB, van der Kleijn E and Bialer M. Pharmacokinetics and Anticonvulsant Activity of Three Monoesteric Prodrugs of Valproic acid. Pharm Res 1991; 8:750–753
Bak A, Gudmundsson OS, Friis GJ, Siahaan TJ and Borchardt RT. Acyloxy-Alkoxy-Based Cyclic Prodrugs of Opioid Peptides: Evaluation of the Chemical and Enzymatic Stability as well as Their Transport Properties Across Caco-2 Cell Monolayers. Pharm Res 1999; 16:24–29
Balis FM, Pizzo PA, Butler KM, Hawkins ME, Brouwers P, Husson RN, Jacobsen F, Blaney SM, Gress J, Jarosinski P and Poplack DG. Clinical Pharmacology of 2′,3′-Dideoxyinosine in Human Immunodeficiency Virus-Infected Children. J Infect Dis 1992; 165:99–104
Balzarini J, Cooney DA, Dalal M, Kang G-J, Cupp JE, De Clercq E, Broder S and Johns DG. 2′,3′-Dideoxycytidine: Regulation of its Metabolism and Anti-Retroviral Potency by Natural Pyrimidine Nucleosides and by Inhibitors of Pyrimidine Nucleotide Synthesis. Mol Pharmacol 1987; 32:789–806
Balzarini J, Herdewijn P and De Clercq E. Differential Patterns of Intracellular Metabolism of 2′,3′-Didehydro-2′,3′-Dideoxythymidine and 3′-Azido-2′,3′-Dideoxythymidine, Two Potent Anti-Human Immunodeficiency Virus Compounds. J Biol Chem 1989; 264:6127–6133
Barchi JJ, Jr., Marquez VE, Driscoll JS, Ford H, Jr., Mitsuya H, Shirasaka T, Aoki S and Kelley JA. Potential Anti-AIDS Drugs. Lipophilic, Adenosine Deaminase-Activated Prodrugs. J Med Chem 1991; 34:1647–1655
Barnard EA, Borsodi A, Goodman M, Hill R, Hunter JC, Moroder L, Pasternak GW, Portoghese PS, Przewlocki R and Roques BP. What is the Molecular Basis of Opioid Antinociception and How Does this Information Point to New Drug Design? In: Basbaum A, and Besson JM. Towards a New Pharmacotherapy of Pain. New York, John Wiley & Sons Ltd.; 1991:299–315
Bassiri RM and Utiger R. Metabolism and Excretion of Exogenous Thyrotropin-Releasing Hormone in Humans. J Clin Invest 1973; 52:1616–1619
Battaglia G, La Russa M, Bruno V, Arenare L, Ippolito R, Copani A, Bonina F and Nicoletti F. Systemically Administered D-Glucose Conjugates of 7-Chlorokynurenic Acid are Centrally Available and Exert Anticonvulsant Activity in Rodents. Brain Res 2000; 860:149–156
Beaulieu E, Demeule M, Averill-Bates DA and Beliveau R. The Strongest Expression of P-Glycoprotein is in the Blood-Brain Barrier. In: Couraud P-O, and Scherman D. Biology and Physiology of the Blood-Brain Barrier. New York, Plenum Press; 1996:171–174
Beaulieu E, Demeule M, Ghitescu L and Beliveau R. P-Glycoprotein is Strongly Expressed in the Luminal Membranes of the Endothelium of Blood Vessels in the Brain. Biochem J 1997; 326:539–544
Bertler A, Falck B, Owman C and Rosengren E. Localization of Monoaminergic Blood-Brain Barrier Mechanisms. Pharmacol Rev 1966; 18:369–385
Betz AL. Identification of Hypoxanthine Transport and Xanthine Oxidase Activity in Brain Capillaries. J Neurochem 1985; 44:574–579
Betz AL and Goldstein GW. Developmental Changes in Metabolism and Transport Properties of Capillaries Isolated from Rat Brain. J Physiol 1981; 312:365–376
Betz AL, Firth JA and Goldstein GW. Polarity of the Blood-Brain Barrier: Distribution of Enzymes Between the Luminal and Antiluminal Membranes of Brain Capillary Endothelial Cells. Brain Res 1980; 192:17–28
Bickel U and Kang Y-S. Use of Chimeric Peptides in Drug Delivery to the Brain. In: Paulson O, Knudsen GM, and Moos T. Brain Barrier Systems. Alfred Benzon Symposium 45, Copenhagen, Munksgaard; 1999; 478–488
Bickel U, Yoshikawa T, Landaw EM, Faull KF and Pardridge WM. Pharmacological Effects In Vivo in Brain by Vector-Mediated Delivery of Peptides. Proc Natl Acad Sci USA 1993; 90:2618–2622
Bickel U, Kang Y-S and Pardridge WM. In Vivo Cleavability of a Disulfide-Based Chimeric Opioid Peptide in Rat Brain. Bioconjug Chem 1995; 6:211–218
Bickel U, Yoshikawa T and Pardridge WM. Delivery of Peptides and Proteins through the Blood-Brain Barrier. Adv Drug Del Rev 2001; 46:247–279
Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB and Johnson MR. Induction of Thymidine Phosphorylase in Both Irradiated and Shielded, Contralateral Human U87MG Glioma Xenografts: Implications for a Dual Modality Treatment Using Capecitabine and Irradiation. Mol Cancer Ther 2002; 1:1139–1145
Block E and Bennett J. Pharmacological Studies with 5-Fluorocytosine. Med Radiol (Mosk) 1974; 19:476–482
Boado RJ, Li JY, Nagaya M, Zhang C and Pardridge WM. Selective Expression of the Large Neutral Amino Acid Transporter at the Blood-Brain Barrier. Proc Natl Acad Sci USA 1999; 96:12079–12084
Boddy A, Aarons L and Petrak K. Efficiency of Drug Targeting: Steady-State Considerations Using a Three-Compartment Model. Pharm Res 1989; 6:367–372
Bodor N. Drug Targeting and Retrometabolic Drug Design Approaches. Adv Drug Del Rev 1994; 14:157–166
Bodor N. Retrometabolic Approaches to Drug Targeting. NIDA Res Monogr Series 1995; 154:1–26
Bodor N and Brewster M. Problems of Delivery of Drugs to the Brain. Pharmacol Ther 1983; 19:337–386
Bodor N and Prokai L. Molecular Packaging. Peptide Delivery to the Central Nervous System by Sequential Metabolism. In: Taylor MD, and Amidon GL. Peptide-Based Drug Design: Controlling Transport and Metabolism, American Chemical Society; 1995; 317–337
Bodor N and Buchwald P. Recent Advances in the Brain Targeting of Neuropharmaceuticals by Chemical Delivery Systems. Adv Drug Del Rev 1999; 36:229–254
Bodor N, Prokai L, Wu W-M, Farag H, Jonalagadda S, Kawamura M and Simpkins J. A Strategy for Delivering Peptides into the Central Nervous System by Sequential Metabolism. Science 1992; 257:1698–1700
Bonina FP, Arenare L, Ippolito R, Boatto G, Battaglia G, Bruno V and De Caprariis P. Synthesis, Pharmacokinetics and Anticonvulsant Activity of 7-Chlorokynurenic Acid Prodrugs. Int J Pharm 2000; 202:79–88
Bonina F, Puglia C, Rimoli MG, Melisi D, Boatto G, Nieddu M, Calignano A, Rana GL and De Caprariis P. Glycosyl Derivatives of Dopamine and L-Dopa as Anti-Parkinson Prodrugs: Synthesis, Pharmacological Activity and In Vitro Stability Studies. J Drug Target 2003; 11:25–36
Bourke RS, West CR, Chheda G and Tower DB. Kinetics of Entry and Distribution of 5-Fluorouracil in Cerebrospinal Fluid and Brain following Intravenous Injection in a Primate. Cancer Res 1973; 33:1735–1746
Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, Colquhoun I, Lewis P and Brampton MH. Multicentre CRC Phase II Trial of Temozolomide in Recurrent or Progressive High-Grade Glioma. Cancer Chemother Pharmacol 1997; 40:484–488
Bradbury MWB. Physiology and Pharmacology of the Blood-Brain Barrier. Berlin: Springer-Verlag; 1992. 549 p
Bradbury A, Finnie M and Smith D. Mechanism of C-Terminal Amide Formation of Pituitary Enzyme. Nature 1982; 298:686–688
Brady TG and O’Donovan CI. A Study of the Tissue Distribution of Adenosine Deaminase in Six Mammal Species. Comp Biochem Physiol 1965; 14:101–120
Bray RC. Molybdenum Iron-Sulfur Flavin Hydrolases and Related Enzymes. In: Boyer PO, Lardy H, and Myrback K. The Enzymes. New York, Academic Press; 1975:533–556
Brecher P, Tercyak A, Gavras H and Chobanian AV. Peptidyl Dipeptidase in Rabbit Brain Microvessels. Biochim Biophys Acta 1978; 526:537–546
Brewster ME and Bodor N. Redox Approaches to Drug Delivery to the Central Nervous System. NIDA Monogr Series 1992; 120:169–201
Brewster ME, Anderson W and Bodor N. Brain, Blood, and Cerebrospinal Fluid Distribution of a Zidovudine Chemical Delivery System in Rabbits. J Pharm Sci 1991; 80:843–846
Brewster ME, Pop E, Braunstein AJ, Pop AC, Druzgala P, Dinculescu A, Anderson W, Elkoussi A and Bodor N. The Effect of Dihydronicotinate N-Substitution on the Brain-Targeting Efficacy of a Zidovudine Chemical Delivery System. Pharm Res 1993; 10:1356–1362
Brewster ME, Raghavan K, Pop E and Bodor N. Enhanced Delivery of Ganciclovir to the Brain through the Use of Redox Targeting. Antimicrob Agents Chemother 1994; 38:817–823
Brewster ME, Anderson WR, Helton DO, Bodor N and Pop E. Dose-Dependent Brain Delivery of Zidovudine through the Use of a Zidovudine Chemical Delivery System. Pharm Res 1995; 12:796–798
Brewster ME, Anderson WR, Webb AI, Pablo LM, Meinsma D, Moreno D, Derendorf H, Bodor N and Pop E. Evaluation of a Brain-Targeting Zidovudine Chemical Delivery System in Dogs. Antimicrob Agents Chemother 1997; 41:122–128
Brightman MW. Morphology of Blood-Brain Interfaces. Exp Eye Res 1977; 25(Suppl.): 1–25
Brightman MW and Reese TS. Junctions between Intimately Apposed Cell Membranes in the Vertebrate Brain. J Cell Biol 1969; 40:648–677
Brightman MW and Tao-Cheng JH. Tight Junctions of Brain Endothelium and Epithelium. In: Pardridge WM. The Blood-Brain Barrier: Cellular and Molecular Biology. New York, Raven Press; 1993:107–125
Brouwers P (1991). Treatment-Related Changes in Pediatric Cognitive Function. Workshop on Neuro-AIDS: Drug Discovery and Development, Portland, Maine
Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG, Black PM, Breakefield XO and Aboody KS. Intravascular Delivery of Neural Stem Cell Lines to Target Intracranial and Extracranial Tumors of Neural and Non-Neural Origin. Hum Gene Ther 2003; 14:1777–1785
Brownlees J and Williams CH. Peptidase, Peptides, and the Mammalian Blood-Brain Barrier. J Neurochem 1993; 60:793–803
Buchwald P and Bodor N. Quantitative Structure-Metabolism Relationships: Steric and Nonsteric Effects in the Enzymatic Hydrolysis of Noncongener Carboxylic Esters. J Med Chem 1999; 42:5160–5168
Bundgaard H. The Double Prodrug Concept and its Applications. Adv Drug Deliv Rev 1989; 3:39–66
Burns CL, Clair MHS, Frick LW, Spector T, Averett DR, English ML, Holmes TJ, Krenitsky TA and Koszalka GW. Novel 6-Alkoxypurine 2’,3’-Dideoxynucleosides as Inhibitors of the Cytopathic Effect of the Human Immunodeficiency Virus. J Med Chem 1993; 36:378–384
Busby J, W. H., Quackenbush GE, Humm J, Youngblood W and Kizer JS. An Enzyme(s) that Converts Glutaminyl-Peptides into Pyroglutamyl Peptides. Presence in Pituitary, Brain, Adrenal Medulla, and Lymphocytes. J Biol Chem 1982; 262:8532–8536
Butler KM, Husson RN, Balis FM, Brouwers P, Eddy J, El-Amin D, Gress J, Hawkins M, Jarosinski P, Moss H, Poplack D, Santacroce S, Venzon D, Wiener L, Wolters P and Pizzo PA. Dideoxyinosine in Children with Symptomatic Human Immunodeficiency Virus Infection. N Engl J Med 1991; 324:137–144
Carelli V, Liberatore F, Scipione L, Impicciatore M, Barocelli E, Cardellini M and Giorgioni G. New Systems for the Specific Delivery and Sustained Release of Dopamine to the Brain. J Control Release 1996; 42:209–216
Ceresoli-Borroni G, Guidetti P and Schwarz R. Acute and Chronic Changes in Kynurenate Formation following an Intrastriatal Quinolinate Injection in Rats. J Neural Transm 1999; 106:229–242
Chassy BM and Suhadolnik RJ. Adenosine Aminohydrolase. Binding and Hydrolysis of 2-and 6-Substituted Purine Ribonucleosides and 9-Substituted Adenine Nucleosides. J Biol Chem 1967; 242:3655–3658
Chen H, Noble F, Roques BP and Fournié-Zaluski M-C. Long Lasting Antinociceptive Properties of Enkephalin Degrading Enzyme (NEP and APN) Inhibitor Prodrugs. J Med Chem 2001; 44:3523–3530
Chen W, Yang JZ, Andersen R, Nielsen LH and Borchardt RT. Evaluation of the Permeation Characteristics of a Model Peptide Opioid Peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its Cyclic Prodrugs across the Blood-Brain Barrier Using an In Situ Perfused Rat Brain Model. J Pharmacol Exp Ther 2002; 303:849–857
Chen P, Bodor N, Wu W-M and Prokai L. Strategies to Target Kyotorphin Analogues to the Brain. J Med Chem 1998; 41:3773–3781
Chipkin RE. Inhibitors of Enkephalinase: The Next Generation of Analgesics. Drugs Future 1986; 11:593–607
Chu CK, Bhadti VS, Doshi KJ, Etse JT, Gallo JM, Boudinot FD and Schinazi RF. Brain Targeting of Anti-HIV Nucleosides: Synthesis and In Vitro and In Vivo Studies of Dihydropyridine Derivatives of 3′-Azido-2′,3′-Dideoxyuridine and 3′-Azido-3′-Deoxythymidine. J Med Chem 1990a; 33:2188–2192
Chu CK, Ullas GV, Jeong LS, Ahn SK, Doboszewski B, Lin ZX, Beach JW and Schinazi RF. Synthesis and Structure-Activity Relationships of 6-Substituted 2′,3′-Dideoxypurine Nucleosides as Potential Anti-Human Immunodeficiency Virus Agents. J Med Chem 1990b; 33:1553–1561
Cook CS, Karabatsos PJ, Schoenhard GL and Karim A. Species Dependent Esterase Activities for Hydrolysis of an Anti-HIV Prodrug Glycovir and Bioavailability of Active SC-48334. Pharm Res 1995; 12:1158–1164
Cooper AJL. The Role of Glutamine Transaminase K (GTK) in Sulfur and α-Keto Acid Metabolism in the Brain, and in the Possible Bioactivation of Neurotoxicants. Neurochem Int 2004; 44:557–577
Cooper DR, Marrel C, Van de Waterbeemd H, Testa B, Jenner P and Marsden CD. L-Dopa Esters as Potential Prodrugs: Behavioral Activity in Experimental Models of Parkinson’s Disease. J Pharm Pharmacol 1987a; 39:627–635
Cooper DR, Marrel C, Van de Waterbeemd H, Testa B, Jenner P and Marsden CD. L-Dopa Esters as Potential Prodrugs: Effect on Brain Concentration of Dopamine Metabolites in Reserpinized Mice. J Pharm Pharmacol 1987b; 39:809–818
Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR and Bertino JR. Multidrug-Resistance Gene (P-Glycoprotein) is Expressed by Endothelial Cells at Blood-Brain Barrier Sites. Proc Natl Acad Sci USA 1989; 86:695–698
Crider AM, Tita JD, Wood JD and Hinko CN. Esters of Nipecotic Acid and Iso-Nipecotic Acid as Potential Anticonvulsants. J Pharm Sci 1982; 71:1214–1219
Crider AM, Wood JD, Tschappat KD, Hinko CN and Seibert K. γ-Aminobutyric Acid Uptake Inhibition and Anticonvulsant Activity of Nipecotic Acid Esters. J Pharm Sci 1984; 73:1612–1616
Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH and Blaese RM. In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors. Science 1992; 256:1550–1552
Dallaire L, Tremblay L and Beliveau R. Purification and Characterization of Metabolically Active Capillaries of the Blood-Brain Barrier. Biochem J 1991; 276:745–752
de Varebeke PJ, Cavalier R, David-Ramacle M and Youdim MBH. Formation of the Neurotransmitter Glycine from the Anticonvulsant Milacemide is Mediated by Brain Monoamine Oxidase B. J Neurochem 1988; 50:1011–1016
DeGraw RT and Anderson BD. Enhanced Oral Bioavailability of 2′-β-Fluoro-2′,3′-Dideoxyadenosine (F-ddA) through Local Inhibition of Intestinal Adenosine Deaminase. Pharm Res 2001; 18:1270–1276
Deguchi Y and Morimoto K. Application of an In Vivo Brain Microdialysis Technique to Studies of Drug Transport across the Blood-Brain Barrier. Current Drug Metab 2001; 2:411–423
Deguchi Y, Inabe K, Tomiuasu K, Nozawa K, Yamada S and Kimura R. Study on Brain Interstitial Fluid Distribution and Blood-Brain Barrier Transport of Baclofen in Rats by Microdialysis. Pharm Res 1995; 12:1838–1844
Deguchi Y, Hayashi H, Fujii S, Naito T, Yokoyama Y, Yamada S and Kimura R. Improved Brain Delivery of a Nonsteroidal Anti-Inflammatory Drug with a Synthetic Glyceride Ester: A Preliminary Attempt at a CNS Drug Delivery System for the Therapy of Alzheimer’s Disease. J Drug Target 2000; 8:371–381
Denny BJ, Wheelhouse RT, Stevens MFG, Tsang LLH and Slack JA. NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNA. Biochemistry 1994; 33:9045–9051
DePierre JW and Morgenstern R. Comparison of the Distribution of Microsomal and Cytosolic Glutathione S-Transferase Activities in Different Organs of the Rat. Biochem Pharmacol 1983; 32:721–723
Dixon M and Webb E. Enzymes. New York, Academic; 1979. 1116 p
Djuricic BM and Mrsulja BB. Enzymic Activity of the Brain: Microvessels vs. Total Forebrain Homogenate. Brain Res 1977; 138:561–564
Doheny MH, Shigeru N and Patsalos PN. A Microdialysis Study of Glycinamide, Glycine and Other Amino Acid Neurotransmitters in Rat Frontal Cortex and Hippocampus after the Administration of Milacemide, a Glycine Pro-Drug. Naunyn-Schmiedeberg’s Arch Pharmacol 1996; 354:157–163
Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L, Hirshowitz EA, Crystal R, Weichselbaum R, Kufe DW and Fine HA. In Vivo Replication-Deficient Adenovirus Vector-Mediated Transduction of the Cytosine Deaminase Gene Sensitizes Glioma Cells to 5-Fluorocytosine. Hum Gene Ther 1996; 7:713–720
Drewes LR and Betz AL, Eds. Drewes LR and Betz AL, Eds. Frontiers in Cerebral Vascular Biology: Transport and Its Regulation Advances in Experimental Medicine and Biology New York, Plenum Press; 1993. 295 p
Driscoll JS. AIDS: Adenosine Deaminase-Activated Prodrugs Designed for the Treatment of Human Immunodeficiency Virus in the Central Nervous System. In: Torrence PF. Biomedical Chemistry: Applying Chemical Principles to the Understanding and Treatment of Disease. New York: John Wiley & Sons, Inc.; 2000:99–114
Driscoll JS, Siddiqui MA, Ford J, H., Kelley JA, Roth JS, Mitsuya H, Tanaka M and Marquez VE. Lipophilic, Acid-Stable, Adenosine Deaminase-Activated Anti-HIV Prodrugs for Central Nervous System Delivery. 3. 6-Amino Prodrugs of 2′-β-Fluoro-2′,3′-Dideoxyinosine. J Med Chem 1996; 39:1619–1625
Durrer A, Walther B, Racciatti A, Boss G and Testa B. Structure-Metabolism Relationships in the Hydrolysis of Nicotinate Esters by Rat Liver and Brain Subcellular Fractions. Pharm Res 1991; 8:832–839
Dykstra KH, Arya A, Arriola DM, Bungay PM, Morrison PF and Dedrick RL. Microdialysis Study of Zidovudine (AZT) Transport in Rat Brain. J Pharmacol Exp Ther 1993; 267:1227–1236
Eraly SA, Hamilton BA and Nigam SK. Organic Anion and Cation Transporters Occur in Pairs of Similar and Similarly Expressed Genes. Biochem Biophys Res Commun 2003; 300:333–342
Erb C, Seidel A, Frank H, Platt KL, Oesch F and Klein J. Formation of N-Methylnicotinamide in the Brain from a Dihydroyridine-Type Prodrug. Biochem Pharm 1999; 57:681–684
Estonius M, Forsberg L, Danielsson O, Weinander R, Kelner MJ and Morgenstern R. Distribution of Microsomal Glutathione Transferase 1 in Mammalian Tissues. A Predominant Alternate First Exon in Human Tissues. Eur J Biochem 1999; 260:409–413
Ezzeddine ZD, Martuza RL, Platika D, short MP, Malick A, Choi B and Breakefield XO. Selective Killing of Glioma Cells in Culture and In Vivo by Retrovirus Transfer of the Herpes Virus Thymidine Kinase Gene. Nature Biol 1991; 3:608–614
Faden AI, Vink R and McIntosh TK. Thyrotropin-Releasing Hormone and Central Nervous System Trauma. Ann N Y Acad Sci 1989; 553:380–384
Farrell CL and Pardridge WM. Blood-Brain Barrier Glucose Transporter is Asymmetrically Distributed on Brain Capillary Endothelial Lumenal and Ablumenal Membranes: An Electron Microscopic Immunogold Study. Proc Natl Acad Sci 1991; 88:5779–5783
Feener EP, Shen W-C and Ryser HJP. Cleavage of Disulfide Bonds in Endocytosed Macromolecules. J Biol Chem 1990; 265:18780–18785
Fenstermacher JD and Rapoport SI. Blood-Brain Barrier. In: Renkin EM, and Michel CC. Handbook of Physiology Section 2: The Cardiovascular System Vol IV: Microcirculation. Washington, D.C., American Physiological Society; 1984:969–1000
Fernandez C, Nieto O, Fontenla JA, Rivas E, de Ceballos ML and Fernandez-Mayoralas A. Synthesis of Glycosyl Derivatives as Dopamine Prodrugs: Interaction with Glucose Carrier GLUT-1. Org Biomol Chem 2003; 1:767–771
Finberg JPM and Youdim MBH. Monoamine Oxidases. In: Lajtha A. Handbook of Neurochemistry. New York, Plenum Press; 1983:293–313
Fischer W and Spiess J. Identification of a Mammalian Glutaminyl Cyclase Converting Glutaminyl into Pyroglutaminyl Peptides. Proc Natl Acad Sci USA 1987; 84:3628–3632
Flaherty P, Castagnoli K, Wang Y-X and Castagnoli J, N. Synthesis and Selective Monoamine Oxidase-B-Inhibiting Properties of 1-Methyl-1,2,3,6-Tetrahydropyrid-4-yl Carbamate Derivatives: Potential Prodrugs of (R)-and (S)-Nordeprenyl. J Med Chem 1996; 39:4756–4761
Ford H, Jr., Siddiqui MA, Driscoll JS, Marquez VE, Kelley JA, Mitsuya H and Shirasaka T. Lipophilic, Acid-Stable, Adenosine Deaminase-Activated Anti-HIV Prodrugs for Central Nervous System Delivery. 2. 6-Halo and 6-Alkoxy Prodrugs of 2′-β-Fluoro-2′,3′-Dideoxyinosine. J Med Chem 1995; 38:1189–1195
Fournie-Zaluski M-C, Coric P, Turcaud S, Bruetschy L, Lucas E, Noble F and Roques BP. Potent and Systemically Active Aminopeptidase N Inhibitors Designed from Active-Site Investigation. J Med Chem 1992a; 35:1259–1266
Fournie-Zaluski M-C, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R and Roques BP. “Mixed Inhibitor-Prodrug” as a New Approach toward Systemically Active Inhibitors of Enkephalin-Degrading Enzymes. J Med Chem 1992b; 35:2473–2481
Frey HH, Popp C and Loscher W. Influence of Inhibitors of the High Affinity GABA Uptake on Seizure Thresholds in Mice. Neuropharmacol 1979; 18:581–590
Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B and Starzyk RM. Anti-Transferrin Receptor Antibody and Antibody-Drug Conjugate across the Blood-Brain Barrier. Proc Natl Acad Sci USA 1991; 88:4771–4775
Furman PA, Fyfe JA, Clair MHS, Weinhold K, Rideout JL, Freeman GA, Nusinoff Lehrman S, Bolognesi DP, Broder S, Mitsuya H and Barry DW. Phosphorylation of 3′-Azido-3′-Deoyxthymidine and Selective Interaction of the 5′-Triphosphate with Human Immunodeficiency Virus Reverse Transcriptase. Proc Natl Acad Sci USA 1986; 83:8333–8337
Galinsky RE, Hoesterey BL and Anderson BD. Brain and Cerebrospinal Fluid Uptake of Zidovudine (AZT) in Rats after Intravenous Injection. Life Sci 1990; 47:781–788
Galinsky RE, Flaharty KK, Hoesterey BL and Anderson BD. Probenecid Enhances Central Nervous System Uptake of 2′,3′-Dideoxyinosine by Inhibiting Cerebrospinal Fluid Efflux. J Pharmacol Exp Ther 1991; 257:972–978
Gallo JM, Etse JT, Doshi KJ, Boudinot FD and Chu CK. Hybrid Pharmacokinetic Models to Describe Anti-HIV Nucleoside Brain Disposition following Parent and Prodrug Administration in Mice. Pharm Res 1991; 8:247–253
Gao W-Y, Shirasaka T, Johns DG, Broder S and Mitsuya H. Differential Phosphorylation of Azidothymidine, Dideoxycytidine, and Dideoxyinosine in Resting and Activated Peripheral Blood Mononuclear Cells. J Clin Invest 1993; 91:2326–2333
Gao W-Y, Agbaria R, Driscoll JS and Mitsuya H. Divergent Anti-Human Immunodeficiency Virus Activity and Anabolic Phosphorylation of 2′,3′-Dideoxynucleoside Analogs in Resting and Activated Human Cells. J Biol Chem 1994; 269:12633–12638
Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A and Meier PJ. Organic Anion-Transporting Polypeptides Mediate Transport of Opioid Peptides across Blood-Brain Barrier. J Pharmacol Exp Ther 2000; 294:73–79
Ge K, Xu L, Zheng Z, Xu D, Sun L and Liu X. Transduction of Cytosine Deaminase Gene Makes Rat Glioma Cells Highly Sensitive to 5-Fluorocytosine. Int J Cancer 1997; 71:675–679
Ghersi-Egea JF, Leninger-Muller B, Suleman G, Siest G and Minn A. Localization of Drug-Metabolizing Enzyme Activities to Blood-Brain Interfaces and Circumventricular Organs. J Neurochem 1994; 62:1089–1096
Ghersi-Egea J-F, Minn A and Siest G. A New Aspect of the Protective Functions of the Blood-Brain Barrier: Activities of Four Drug-Metabolizing Enzymes in Isolated Rat Brain Microvessels. Life Sci 1988; 42:2515–2523
Gohlke P, Urbach H, Scholkens B and Unger T. Inhibition of Converting Enzyme in the Cerebrospinal Fluid of Rats after Oral Treatment with Converting Enzyme Inhibitors. J Pharmacol Exp Ther 1989; 249:609–616
Gomori G. The Distribution of Phosphatase in Normal Organs and Tissues. J Cell Comp Physiol 1941; 17:71–83
Gramsbergen JBP, Hodgkins PS, Rassoulpour A, Turski WA, Guidetti P and Schwarcz R. Brain-Specific Modulation of Kynurenic Acid Synthesis in the Rat. J Neurochem 1997; 69:290–298
Greig NH. Drug Delivery to the Brain by Blood-Brain Barrier Circumvention and Drug Modification. In: Neuwelt EA. Implications of the Blood-Brain Barrier and Its Manipulation. New York, Plenum; 1989:311–367
Greig NH, Daly EM, Sweeney DJ and Rapoport SI. Pharmacokinetics of Chlorambucil-Tertiary Butyl Ester, a Lipophilic Chlorambucil Derivative that Achieves and Maintains High Concentrations in Brain. Cancer Chemother Pharmacol 1990a; 25:311–319
Greig NH, Soncrant TT, Shetty HU, Momma S and Smith QR. Brain Uptakes and Anticancer Activities of Vincristine and Vinblastine are Restricted by their Low Cerebrovascular Permeability and Binding to Plasma Constituents in Rat. Cancer Chemother Pharmacol 1990b; 26:263–268
Groothuis DR and Levy RM. The Entry of Antiviral and Antiretroviral Drugs into the Central Nervous System. J NeuroVirology 1997; 3:387–400
Guidetti P, Okuno E and Schwarcz R. Characterization of Rat Brain Kynurenine Amino-Transferases I and II. J Neurosci Res 2000; 50:457–465
Gunther W, Pawlak E, Damasceno R, Arnold H and Terzis AJ. Temozolomide Induces Apoptosis and Senescence in Glioma Cells Cultured as Multicellular Spheroids. Br J Cancer 2003; 88:463–469
Guyon A, Roques BP, Guyon F, Foucault A, Perdrisot R, Swerts JP and Schwartz JC. Enkephalin Degradation in Mouse Brain Studied by a New HPLC Method: Further Evidence for the Involvement of a Carboxydipeptidase. Life Sci 1979; 25:1605–1612
Handelmann GE, Nevins ME, Mueller LL, Arnolde SM and Cordi AA. Milacemide, a Glycine Prodrug, Enhances Performance of Learning Tasks in Normal and Amnestic Rodents. Pharmacol Biochem Behav 1989; 34:823–828
Hao Z, Cooney DA, Hartman NR, Perno CF, Fridland A, DeVico AL, Sarngadharan MG, Broder S and Johns DG. Factors Determining the Activity of 2′,3′-Dideoxynucleosides in Suppressing Human Immunodeficiency Virus In Vitro. Mol Pharmacol 1988; 34:431–435
Hao Z, Cooney DA, Farquhar D, Perno CF, Zhang K, Masood R, Wilson Y, Hartman NR, Balzarini J and Johns DG. Potent DNA Chain Termination Activity and Selective Inhibition of Human Immunodeficiency Virus Reverse Transcriptase by 2′,3′-Dideoxyuridine-5′-Triphosphate. Mol Pharmacol 1990; 37:157–163
Hardebo JE and Owman C. Barrier Mechanisms for Neurotransmitter Monoamines and their Precursors at the Blood-Brain Barrier. Ann Neurol 1979; 8:1–11
Hardebo JE and Owman C. Characterization of the In Vitro Uptake of Monoamines into Brain Microvessels. Acta Physiol Scand 1980; 108:223–229
Hardebo JE, Falck B, Owman C and Rosengren E. Studies on the Enzymatic Blood-Brain Barrier: Quantitative Measurements of DOPA Decarboxylase in the Wall of Microvessels as Related to the Parenchyma in Various CNS Regions. Acta Physiol Scand 1979; 105:453–460
Hardebo JE, Emson PC, Falck B, Owman C and Rosengren E. Enzymes Related to Monoamine Transmitter Metabolism in Brain Microvessels. J Neurochem 1980; 35:1388–1393
Hasegawa M, Kusuhara H, Endou H and Sugiyama Y. Contribution of Arganic anion Transporters to the Renal Uptake of Anionic Compounds and Nucleoside Derivatives in Rat. J Pharmacol Exp Ther 2003; 305:1087–1097
Hawkins ME, Mitsuya H, McCully CM, Godwin KS, Murakami K, Poplack DG and Balis FM. Pharmacokinetics of Dideoxypurine Nucleoside Analogs in Plasma and Cerebrospinal Fluid of Rhesus Monkeys. Antimicrob Agents Chemother 1995; 39:1259–1264
Hedaya MA and Sawchuk RJ. Effect of Probenecid on the Renal and Nonrenal Clearances of Zidovudine and its Distribution into Cerebrospinal Fluid in the Rabbit. J Pharm Sci 1989; 78:716–722
Henin Y, Gouyette C, Schwartz O, Debouzy J-C, Neumann J-M and Huynh-Dinh T. Lipophilic Glycosyl Phosphotriester Derivatives of AZT: Synthesis, NMR Transmembrane Transport Study, and Antiviral Activity. J Med Chem 1991; 34:1830–1837
Hersh LB, Aboukhair N and Watson S. Immunohistochemical Localization of Aminopeptidase M in Rat Brain and Periphery: Relationship of Enzyme Localization and Enkephalin Metabolism. Peptides 1987; 8:523–532
Hesse GW, Jacob JN and Shashoua VE. Uptake in Brain and Neurophysiological Activity of Two Lipid Esters of γ-Aminobutyric Acid. Neuropharmacol 1988; 27:637–640
Hinko CN, Seibert K and Crider AM. Anticonvulsant Activity of the Nipecotic Acid Ester, (+/−)-m-Nitrophenyl-3-Piperidine Carboxylate. Neuropharmacology 1984; 23:1009–1014
Hinko CN, Crider AM and Wood JD. A Comparison of Prodrug Esters of Nipecotic Acid. Neuropharmacol 1988; 27:475–483
Ho DHW, Pincus C, Carter CJ, Benjamin RS, Freireich EJ and Bodey S, G. P. Distribution and Inhibition of Adenosine Deaminase in Tissues of Man, Rat, and Mouse. Cancer Treat Rep 1980; 64:629–633
Hoesterey BL, Galinsky RE and Anderson BD. Dose Dependence in the Plasma Pharmacokinetics and Uptake Kinetics of 2′,3′-Dideoxyinosine (ddI) into Brain and CSF of Rats. Drug Metab Disp 1991; 19:907–912
Hokari M, Wu H-Q, Schwarcz R and Smith QR. Facilitated Brain Uptake of 4-Chlorokynurenine and Conversion to 7-Chlorokynurenic Acid. NeuroReport 1996; 8:15–18
Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF and Miller DW. Expression of Multidrug Resistance-Associated Protein (MRP) in Brain Microvessel Endothelial Cells. Biochem Biophys Res Commun 1998; 243:816–820
Husain I and Tate SS. Formation of the COOH-Terminal Amide Group of Thyrotropin-Releasing Factor. FEBS Lett 1983; 152:277–281
Inomata K, Yoshioka T, Nasu F and Mayahara H. Ultracytochemical Studies of Capillary Endothelial Cells in the Rat Central Nervous System. Acta Anat 1984; 118:243–248
Ishii-Morita H, Agbaria R, Mullen CA, Hirano H, Koeplin DA, Ram Z, Oldfield EH, Johns DG and Blaese RM. Mechanism of “Bystander Effect” Killing in the Herpes Simplex Thymidine Kinase Gene Therapy Model of Cancer. Gene Ther 1997; 4:244–251
Ishikura T, Senou T, Ishihara H, Kato T and Ito T. Drug Delivery to the Brain. DOPA Prodrugs Based on a Ring-Closure Reaction to Quaternary Thiazolium Compounds. Int J Pharm 1995; 116:51–63
Itoh Y, Ogasawara T, Mushiori A, Yamazaki A, Ukai Y and Kimura KJ. Effect of NS-3, a Thyrotropin-Releasing Hormone Analog, on In Vivo Acetylcholine Release in Rat Brain: Regional Differences and its Sites of Action. J Pharmacol Exp Ther 1994; 271:884–890
Izquierdo M, Cortes M, De Felipe P, Martin V, Diezguerra J, Talavera A and Perez-Higueras A. Long-Term Rat Survival after Malignant Brain Tumour Regression by Retroviral Gene Therapy. Gene Ther 1995; 2:66–69
Jackson I. Controversies in TRH Biosynthesis and Strategies towards the Identification of a TRH Precursor. Ann NY Acad Sci 1989; 553:71–75
Jacob JN, Shashoua VE, Campbell A and Baldessarini RJ. γ-Aminobutyric Acid Esters. 2. Synthesis, Brain Uptake, and Pharmacological Properties of Lipid Esters of γ-Aminobutyric Acid. J Med Chem 1985; 28:106–110
Jacob JN, Hesse GW and Shashoua VE. Synthesis, Brain Uptake, and Pharmacological Properties of a Glyceryl Lipid Containing GABA and the GABA-T Inhibitor γ-vinyl-GABA. J Med Chem 1990; 33:733–736
Jacobs AH, Winkeler A, Dittmar C, Vollmar S, Wienhard K, Reszka R, Voges J and Heiss W-D. Positron-Emission Tomography Monitoring of Anti-Glioblastoma HSV-1-TK Gene Therapy. Gene Ther Reg 2002; 2:49–57
Janinis J, Efstathiou E, Panopoulos C, Samantas E, Aravantinos G, Christodoulou C and Skarlos D. Phase II Study of Temozolomide in Patients with Relapsing High Grade Glioma and Poor Performance Status. Med Oncol 2000; 17:106–110
Jefferies AA, Brandon MR, Hunt SV, Williams AF, Gatter KC and Mason DY. Transferrin Receptor on Endothelium of Brain Capillary. Nature 1984; 312:162–163
Jette L and Beliveau R. P-Glycoprotein is Strongly Expressed in Brain Capillaries. In: Drewes LR, and Betz AL. Frontiers in Cerebral Vascular Biology: Transport and Its Regulation. New York, Plenum Press; 1993:121–125
Johnson M and Fridland A. Phosphorylation of 2′,3′-Dideoxyinosine by Cytosolic 5′-Nucleotidase of Human Lymphoid Cells. Mol Pharmacol 1989; 36:291–295
Johnson MD and Anderson BD. Localization of Purine Metabolizing Enzymes in Bovine Brain Microvessel Endothelial Cells: An Enzymatic Blood-Brain Barrier for Dideoxynucleosides? Pharm Res 1996; 13:1881–1886
Johnson MD and Anderson BD. Use of Cultured Cerebral Capillary Endothelial Cells in Modeling the Central Nervous System Availability of 2′,3′-Dideoxyinosine. J Pharm Sci 2000; 89:322–335
Johnson MA, Ahluwalia G, Connelly MC, Cooney DA, Broder S, Johns DG and Fridland A. Metabolic Pathways for the Activation of the Antiretroviral Agent 2′,3′-Dideoxyadenosine in Human Lymphoid Cells. J Biol Chem 1988; 263:15354–15357
Jones RJ and Bischofberger N. Minireview: Nucleotide Prodrugs. Antiviral Res 1995; 27:1–17
Jones DB, Rustgi VK, Kornhauser DM, Woods A, Quinn R, Hoofnagle JH and Jones EA. The Disposition of 6-Deoxyacyclovir, a Xanthine Oxidase-Activated Prodrug of Acyclovir, in the Isolated Perfused Rat Liver. Hepatology 1987; 7:345–348
Kalaria RN and Harik SI. Blood-Brain Barrier Monoamine Oxidase: Enzyme Characterization in Cerebral Microvessels and Other Tissues from Six Mammalian Species, including Humans. J Neurochem 1987; 49:856–864
Kawaguchi T, Ishikawa K, Seki T and Juni K. Ester Prodrugs of Zidovudine. J Pharm Sci 1990; 79:531–533
Kikuchi R, Kusuhara H, Sugiyama D and Sugiyama Y. Contribution of Organic Anion Transporter 3 (Slc22a8) to the Elimination of p-Aminohippuric Acid and Benzylpenicillin across the Blood-Brain Barrier. J Pharmacol Exp Ther 2003; 306:51–58
Killian DM and Chikhale PJ. A Bioreversible Prodrug Approach Designed to Shift Mechanism of Brain Uptake for Amino-Acid-Containing Anticancer Agents. J Neurochem 2000; 76:966–974
Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM and Wilkinson GR. The Drug Transporter P-Glycoprotein Limits Oral Absorption and Brain Entry of HIV-1 Protease Inhibitors. J Clin Invest 1998; 101:289–294
Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mlkhtari K, Diquet B, Salzmann JL and Philippon J. A Phase I/II Study of Herpes Simplex Virus Type I Thymidine Kinase “Suicide” Gene Therapy for Recurrent Glioblastoma. Hum Gene Ther 1998; 9:2595–2604
Krause M, Stark H and Schunack W. Azomethine Prodrugs of (R)-α-Methylhistamine, a Highly Potent and Selective Histamine H3-Receptor Agonist. Curr Med Chem 2001; 8:1329–1340
Krenitsky TA, Hall WW, de Miranda P, Beauchamp LM, Schaeffer HJ and Whiteman PD. 6-Deoxyacyclovir: A Xanthine Oxidase-Activated Prodrug of Acyclovir. Proc Natl Acad Sci USA 1984; 81:3209–3213
Krisch K. Carboxylic Ester Hydrolases. In: Boyer P. The Enzymes. London, Academic; 1971:43–69
Krogsgaard-Larsen P and Johnston GAR. Inhibition of GABA Uptake in Rat Brain Slices by Nipecotic Acid, Various Isoxazoles and Related Compounds. J Neurochem 1975; 25:797–802
Kusuhara H and Sugiyama Y. Role of Transporters in the Tissue-Selective Distribution and Elimination of Drugs: Transporters in the Liver, Small Intestine, Brain and Kidney. J Control Rel 2002; 78:43–54
Kusuhara H, Suzuki H, Naito M, Tsuruo T and Sugiyama Y. Characterization of Efflux Transport of Organic Anions in a Mouse Brain Capillary Endothelial Cell Line. J Pharmacol Exp Ther 1998; 285:1260–1265
Lai FM, Berkowitz B and Spector S. Influence of Age on Brain Vascular and Cardiovascular Monoamine Oxidase Activty in the Tat. Life Sci 1978; 22:2051–2056
Lambert DM. Rationale and Applications of Lipids as Prodrug Carriers. Eur J Pharm Sci 2000; 11Suppl. 2:S15–S27
Lambert SM, Mergen F, Poupaert JH and Dumont P. Analgesic Potency of S-Acetylthiorphan after Intravenous Administration to Mice. Eur J Pharmacol 1993; 243:129–134
Lampe T, Norris J, Risse S, Owens-Williams E and Keenan T. Basic Mechanisms, Diagnosis and Therapeutic Strategies. In: Iqbal K, McLachlan DRC, Winbald B, and Wisniewski HM. Alzheimer’s Disease. New York, John Wiley & Sons, Ltd.; 1991:643
Lecomte JM, Costentin J, Vlaiculescu A, Chaillet P, Marcais-Collado H, Llorens-Cortes C, Leboyer M and Schwartz J-C. Pharmacological Properties of Acetorphan, a Parenterally Active “Enkephalinase” Inhibitor. J Pharmacol Exp Ther 1986; 237:937–944
Lee S-C and Schwarcz R. Excitotoxic Injury Stimulates Pro-Drug-Induced 7-Chlorokynurenate Formation in the Rat Striatum In Vivo. Neurosci Lett 2001; 304:185–188
Lee G, Dallas S, Hong M and Bendayan R. Drug Transporters in the Central Nervous System: Brain Barriers and Brain Parenchyma Considerations. Pharmacol Rev 2001; 53:569–596
Leeson PD and Iversen LL. The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential. J Med Chem 1994; 37:4053–4067
Lefebvre I, Perigaud C, Pompon A, Aubertin A-M, Girarder J-L, Kirn A, Gosselin G and Imbach J-L. Mononucleoside Phosphotriester Derivatives with S-Acyl-2-Thioethyl Bioconvertible Phosphate-Protecting Groups: Intracellular Delivery of 3′-Azido-2′,3′-Dideoxythymidine 5′-Monophosphate. J Med Chem 1995; 38:3941–3950
Leisen C, Langguth P, Herbert B, Dressler C, Koggel A and Spahn-Langguth H. Lipophilicities of Baclofen Ester Prodrugs Correlate with Affinities to the ATP-Dependent Efflux Pump P-Glycoprotein: Relevance for their Permeation across the Blood-Brain Barrier. Pharm Res 2003; 20:772–778
Lieb WR and Stein WD. Simple Diffusion across the Membrane Bilayer. In: Stein WD. Transport and Diffusion across Cell Membranes. Orlando, Florida, Academic Press, Inc.; 1986:69–112
Lindsay S, Liu TH, Xu JA, Marshall PA, Thompson JK, Parks DA, Freeman BA, Hsu CY and Beckman JS. Role of Xanthine Dehydrogenase and Oxidase in Focal Cerebral Ischemic Injury to Rat. Am J Physiol 1991; 261:H2051–2057
Little R, Bailey D, Brewster ME, Estes KS, Clemmons RM, Saab A and Bodor N. Improved Delivery through Biological Membranes. XXXIII. Brain-Enhanced Delivery of Azidothymidine (AZT). J Biopharm Sci 1990; 1:1–18
Lodge D, Johansen GAR, Curtis DR and Brand SJ. Effects of Areca Nut Constituents Arecaidine and Guvacine on the Action of GABA in the Cat Central Nervous system. Brain Res 1977; 136:513–522
Lodish HF and Kong N. The Secretory Pathway is Normal in Dithiothreitol-Treated Cells, but Disulfide-Bonded Proteins are Reduced and Reversibly Retained in the Endoplasmic Reticulum. J Biol Chem 1993; 268:20598–20605
Lupia RH, Ferencz N, Aggarwal S, Agrawal KC and Lertora JJL (1991). Pharmacokinetics and Brain Penetration of Zidovudine Derived from Two Novel Prodrugs. AIDS Clinical Trials Group Meeting, July 1991, Bethesda, MD
Lupia RH, Ferencz N, Lertora JJL, Aggarwal SK, George WJ and Agrawal KC. Comparative Pharmacokinetics of Two Prodrugs of Zidovudine in Rabbits: Enhanced Levels of Zidovudine in Brain Tissue. Antimicrob Agents Chemother 1993; 37:818–824
Malfroy B, Swerts JP, Guyon A, Roques BP and Schwartz J-C. High Affinity Enkephalin-Degrading Peptidase in Brain is Increased after Morphine. Nature (Lond) 1978; 276:523–526
Manouilov KK, Manouilova LS, Boudinot FD, Schinazi RF and Chu CK. Biotransformation and Pharmacokinetics of Prodrug 9-(β-D-1,3-Dioxolan-4-yl)-2-Aminopurine and its Antiviral Metabolite 9-((β-D-1,3-Dioxolan-4-yl)Guanine in Mice. Antiviral Res 1997; 35:187–193
Marquez VE, Tseng CK-H, Kelley JA, Mitsuya H, Broder S, Roth JS and Driscoll JS. 2′,3′-Dideoxy-2′-Fluoro-Ara-A. An Acid-Stable Purine Nucleoside Active Against Human Immunodeficiency Virus (HIV). Biochem Pharmacol 1987; 36:2719–2722
Marquez VE, Tseng CK-H, Mitsuya H, Aoki S, Kelley JA, Ford J, H., Roth JS, Broder S, Johns DG and Driscoll JS. Acid-Stable 2′-Fluoro Purine Dideoxynucleosides as Active Agents against HIV. J Med Chem 1990; 33:978–985
Minagawa T, Kohno Y, Suwa T and Tsuji A. Species Differences in Hydrolysis of Isocarbacyclin Methyl Ester (TEI-9090) by Blood Esterases. Biochem Pharmacol 1995; 49:1361–1365
Minn A, Ghersi-Egea J-F, Perrin R, Leininger B and Siest G. Drug Metabolizing Enzymes in the Brain and Cerebral Microvessels. Brain Res Rev 1991; 16:65–82
Mistry G and Drummond GI. Adenosine Metabolism in Microvessels from Heart and Brain. J Mol Cell Cardiol 1986; 18:13–22
Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I and Ishitsuka H. Design of a Novel Oral Fluoropyrimidine Carbamate, Capecitabine, which Generates 5-Fluorouracil Selectively in Tumors by Enzymes Concentrated in Human Liver and Tumor Tissue. Eur J Cancer 1998; 34:1274–1281
Mohamedali KA, Guicherit OM, Kellems RE and Rudolph FB. The Highest Levels of Purine Catabolic Enzymes in Mice are Present in the Proximal Small Intestine. J Biol Chem 1993; 268:23728–23733
Morgan ME, Chi S-C, Murakami K, Mitsuya H and Anderson BD. Central Nervous System Targeting of 2′,3′-Dideoxyinosine via Adenosine Deaminase-Activated 6-Halo-Dideoxypurine Prodrugs. Antimicrob Agents Chemother 1992; 36:2156–2165
Morgan ME, Singhal D and Anderson BD. Quantitative Assessment of Blood-Brain Barrier Damage during Microdialysis. J Pharmacol Exp Ther 1996; 277:1167–1176
Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang Y-S, Hosoya K-I and Terasaki T. Rat Organic Anion Transporter 3 (OAT3) is Responsible for Brain-to-Blood Efflux of Homovanillic Acid at the Abluminal Membrane of Brain Capillary Endothelial Cells. J Cereb Blood Flow Metab 2003; 23:432–440
Morikawa M, Inoue M and Tsuboi M. Substrate Specificity of Carboxylesterase from Several Animals. Chem Pharm Bull 1976; 24:1661–1664
Moriwaki Y, Yamamoto T, Yamaguchi K, Takahashi S and Higashino K. Immunohistochemical Localization of Aldehyde and Xanthine Oxidase in Rat Tissues Using Polyclonal Antibodies. Histochem Cell Biol 1996; 105:71–79
Moriwaki Y, Yamamoto T and Higashino K. Enzymes Involved in Purine Metabolism—A Review of Histochemical Localization and Functional Implications. Histol Histopathol 1999; 14:1321–40
Moriwaki Y, Yamamoto T, Takahashi S, Tsutsumi Z and Hada T. Widespread Cellular Distribution of Aldehyde Oxidase in Human Tissues Found by Immunohistochemistry Staining. Histol Histopathol 2001; 16:745–753
Mullen CA. Transfer of the Bacterial Gene for Cytosine Deaminase to Mammalian Cells Confers Lethal Sensitivity to 5-Fluorocytosine: A Negative Selection System. Proc Natl Acad Sci USA 1992; 89:33–37
Murakami K, Shirasaka T, Yoshioka H, Kojima E, Aoki S, Ford H, Jr., Driscoll JS, Kelley JA and Mitsuya H. Escherichia Coli Mediated Biosynthesis and In Vitro Anti-HIV Activity of Lipophilic 6-Halo-2′,3′-Dideoxypurine Nucleosides J Med Chem 1991; 34:1606–1612
Nafe C, Cao Y-J, Quinones A, Dobberstein K-U, Kramm CM and Rainov NG. Expression of Mutant Non-Cleavable Fas Ligand on Retrovirus Packaging Cells Causes Apoptosis of Immunocompetent Cells and Improves Prodrug Activation Gene Therapy in a Malignant Glioma Model. Life Sci 2003; 73:1847–1860
Namane A, Gouyette C, Fillion M-P, Fillion G and Huynh-Dinh T. Improved Brain Delivery of AZT Using a Glycosyl Phosphotriester Prodrug. J Med Chem 1992; 35:3039–3044
Neuwelt EA, Ed. Implications of the Blood-Brain Barrier and Its Manipulation Vol 1: Basic Science Aspects New York, Plenum Publishing Corp.; 1989. 403 p
Newlands ES, Blackledge GRP, Slacki JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hoffman R, Stevens MFG, Brampton MH and Gibson AC. Phase I Trial of Temozolomide (CCRG 81045:M&B 39831:NSC 362856). Br J Cancer 1992; 65:287–291
Noble F, Soleilhac JM, Soroca-Lucas E, Turcaud S, Fournie-Zaluski MC and Roques BP. Inhibition of the Enkephalin-Metabolizing Enzymes by the First Systemically Active Mixed Inhibitor Prodrug RB 101 Induces Potent Analgesic Responses in Mice and Rats. J Pharmacol Exp Ther 1992; 261:181–190
Nordstrom M, Abrahamsson T, Ervik M, Forshult E and Regardh CG. Central Nervous and Systemic Kinetics of Ramipril and Ramiprilat in the Conscious Dog. J Pharmacol Exp Ther 1993; 266:147–152
O’Brien EM, Tipton KF, Strolin Benedetti M, Bonsignori A, Marrari P and Dostyert P. Is the Oxidation of Milacemide by Monoamine Oxidase a Major Factor in its Anticonvulsant Actions? Biochem Pharmacol 1991; 41:1731–1737
Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K-I, Otagiri M and Terasaki T. Role of Blood-Brain Barrier Organic Anion Transporter 3 (OAT3) in the Efflux of Indoxyl Sulfate, a Uremic Toxin: Its Involvement in Neurotransmitter Metabolite Clearance from the Brain. J Neurochem 2002; 83:57–66
Ohtsuki S, Takizawa T, Takanaga H, Terasaki N, Kitazawa T, Sasaki M, Abe T, Hosoya KI and Terasaki T. In Vitro Study of the Functional Expression of Organic Anion Transporting Polypeptide 3 at Rat Choroid Plexus Epithelial Cells and its Involvement in the Cerebrospinal Fluid-to-Blood Transport of Estrone-3-Sulfate. Mol Pharm 2003; 63:532–537
Oldendorf WH. Brain Uptake of Radiolabeled Amino Acids, Amines, and Hexoses after Arterial Injection. Am J Physiol 1971; 221:1629–1639
Ouyang H, Borchardt RT, Siahaan TJ and Vander Velde D. Synthesis and Conformation Study of a Coumarinic Acid-Based Cyclic Prodrug of Opioid Peptide with Modified Sensitivity to Esterase-Catalyzed Bioconversion. J Pept Res 2002; 59:183–195
Parang K, Knaus EE and Wiebe LI. Synthesis, In Vitro Anti-HIV Activity, and Biological Stability of 5′-O-Myristoyl Analogue Derivatives of 3′-Fluoro-2′,3′-Dideoxythymidine (FLT) as Potential Bifunctional Prodrugs of FLT. Nucleosides Nucleotides 1998a; 17:987–1008
Parang K, Wiebe LI and Knaus EE. Pharmacokinetics and Tissue Distribution of (+)-3′-Azido-2′,3′-Dideoxy-5′-O-(2-Bromomyristoyl)thymidine, a Prodrug of 3′-Azido-2′,3′-Dideoxythymidine(AZT) in Mice. J Pharm Pharmacol 1998b; 50:989–996
Parang K, Wiebe LI and Knaus EE. Synthesis, In Vitro Anti-Human Immunodeficiency Virus Structure-Activity Relationships and Biological Stability of 5′-O-Myristoyl Analog Derivatives of 3′-Azido-2′,3′-Dideoxythymidine (AZT) as Potential Prodrugs. Antiviral Chem Chemother 1998c; 9:311–323
Parang K, Wiebe LI and Knaus EE. Novel Approaches for Designing 5′-O-Ester Prodrugs of 3′-Azido-2′3′-Dideoxythymidine (AZT). Curr Med Chem 2000; 7:995–1039
Pardridge WM. Peptide Drug Delivery to the Brain New York, Raven Press; 1991. 357 p
Pardridge WM. Brain Drug Delivery andBlood-Brain Barrier Transport. Drug Delivery 1993; 1:83–101
Pardridge WM. Brain Drug Targeting: The Future of Brain Drug Development Cambridge, U.K., Cambridge University Press; 2001. 352 p
Pardridge WM. Drug and Gene Delivery to the Brain: The Vascular Route. Neuron 2002; 36:555–558
Pardridge WM, Boado RJ and Farrell CR. Brain-Type Glucose Transporter (GLUT-1) is Selectively Localized to the Blood-Brain Barrier. Studies with Quantitative Western Blotting and In Situ Hybridization. J Biol Chem 1990a; 265:18035–18040
Pardridge WM, Triguero D and Buciak JL. β-Endorphin Chimeric Peptides: Transport through the Blood-Brain Barrier In Vivo and Cleavage of Disulfide Linkage by Brain. Endocrinology 1990b; 126:977–984
Perno CF, Yarchoan R, Cooney DA, Hartman NR, Webb DSA, Hao Z, Mitsuya H, Johns DG and Broder S. Replication of Human Immunodeficiency Virus in Monocytes. J Exp Med 1989; 169:933–951
Pizzo PA. Pediatric AIDS: Problems Within Patients. J Infect Dis 1990; 161:316–325
Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, Moss H, Wolters P, Brouwers P, Jarosinski P, Rubin M, Broder S, Yarchoan R, Brunetti A, Maha M, Nusinoff-Lehrman S and Poplack DG. Effect of Continuous Intravenous Infusion of Zidovudine (AZT) in Children with Symptomatic HIV Infection. N Engl J Med 1988; 319:889–896
Pop E, Loftsson T and Bodor N. Solubilization and Stabilization of a Benzylpenicillin Chemical Delivery System by 2-Hydroxypropyl-β-Cyclodextrin. Pharm Res 1984; 8:1044–1049
Prokai L, Ouyang X, Wu W and Bodor N. Chemical Delivery System to Transport a Puroglutamyl Peptide Amide to the Central Nervous System. J Amer Chem Soc 1994; 116:2643–2644
Prokai L, Prokai-Tatrai K, Ouyang X, Kim H-S, Wu W-M, Zharikova A and Bodor N. Metabolism-Based Brain-Targeting System for a Thyrotropin-Releasing Hormone Analogue. J Med Chem 1999; 42:4563–4571
Prokai L, Prokai-Tatrai K and Bodor N. Targeting Drugs to the Brain by Redox Chemical Delivery Systems. Med Res Rev 2000; 20:367–416
Prokai-Tatrai K, Nguyen V, Zharikova AD, Braddy AC, Stevens J, S. M. and Prokai L. Prodrugs to Enhance Central Nervous System Effects of the TRH-like Peptide pGlu-Glu-Pro-NH2. Bioorg Med Chem Lett 2003; 13:1011–1014
Pu AT, Robertson JM and Lawrence TS. Current Status of Radiation Sensitization by Fluoropyrimidines. Oncology (Huntingt) 1995; 9:707–714
Quon CY, Mai K, Patil G and Stampfli HF. Species Differences in the Stereoselective Hydrolysis of Esmolol by Blood Esterases. Drug Metab Dispos 1988; 16:425–428
Rainov NG. A Phase III Clinical Evaluation of Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Gene Therapy as an Adjuvant to Surgical Resection and Radiation in Adults with Previously Untreated Glioblastoma Multiforme. Hum Gene Ther 2000; 11:2389–2401
Ram Z, Culver KW, Walbridge S, Blaese RM and Oldfield EH. In Situ Retroviral-Mediated Gene Transfer for the Treatment of Brain Tumours in Rats. Cancer Res 1993; 53:83–88
Ranadive SA, Chen AX and Serajuddin ATM. Relative Lipophilicities and Structural-Pharmacological Considerations of Various Angiotensin-Converting Enzyme (ACE) Inhibitors. Pharm Res 1992; 9:1480–1486
Rapoport SI. Blood-Brain Barrier in Physiology and Medicine New York, Raven Press; 1976. 316 p
Rapoport SI, Ohno K and Pettigrew KD. Drug Entry into the Brain. Brain Res 1979; 172:354–359
Raub TJ, Barsuhn CL, Williams LR, Decker DE, Sawada GA and Ho NFH. Use of a Biophysical-Kinetic Model to Understand the Roles of Protein Binding and Membrane Partitioning on Passive Diffusion of Highly Lipophilic Molecules across Cellular Barriers. J Drug Target 1993; 1:269–286
Reese T and Karnovsky M. Fine Structural Localization of a Blood-Brain Barrier to Exogenous Peroxidase. J Cell Biol 1967; 34:207–217
Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, Couraud PO and Roux F. MRP1 Multidrug Resistance-Associated Protein and PGlycoprotein Expression in Rat Brain Microvessel Endothelial Cells. J Neurochem 1998; 71:705–715
Rehemtulla A, Hall DE, Stegman LD, Prasad U, Chen G, Bhojani MS, Chenevert TL and Ross BD. Molecular Imaging of Gene Expression and Efficacy following Adenoviral-Mediated Brain Tumor Gene Therapy. Mol Imaging 2002; 1:43–55
Richter K, Kawashima E, Egger R and Kreil G. Biosynthesis of Thyrotropin-Releasing Hormone in the Skin of Xenopus Laevis: Partial Sequence of the Precursor Deduced from Cloned cDNA. EMBO J 1994; 3:617–621
Roba J, Cavalier R, Cordi A, Gorissen H, Herin M, De Varebeke JP, Onkelinx C, Remacle M and Van Dorsser W. Milacemide. In: Meldrum BS, and Porter RH. New Anticonvulsant Drugs. London, J. Libbey & Co.; 1986:179–190
Robinson PJ and Rapoport SI. Kinetics of Protein Binding Determine Rates of Uptake of Drugs by Brain. Am J Physiol 1986; 351:R1212–R1220
Robinson PJ and Rapoport SI. Transport of Drugs. In: Bradbury MWB. Physiology and Pharmacology of the Blood-Brain Barrier. Berlin, Springer-Verlag; 1992:279–300
Rooseboom M, Commandeur JNM and Vermeulen NPE. Enzyme-Catalyzed Activation of Anticancer Prodrugs. Pharmacol Rev 2004; 56:53–102
Roques BP and Fournie-Zaluski M. Enkephalin Degrading Enzyme Inhibitors: A Physiological Way to New Analgesics and Psychoactive Agents. In: Rapaka RS, and Hawks RL. Opioid Peptides: Molecular, Pharmacology, Biosynthesis and Analysis; 1986:128–154
Roques BP, Lucas-Soroca E, Chaillet P, Costentin J and Fournie-Zaluski MC. The Enkephalinase Inhibitor Thiorphan Shows Antinociceptive Activity in Mice. Nature (Lond) 1980; 288:286–288
Rosowsky A, Abelson H, Beardsley G, Ensminger WD, Kufe DW, Steele G and Modest EJ. Pharmacological Studies on the Dibutyl and γ-Monobutyl Esters of Methotrexate in the Rhesus Monkey. Cancer Chemother Pharmacol 1982; 10:55–61
Roth JS, McCully CM, Balis FM, Poplack DG and Kelley JA. 2′-β-Fluoro-2′,3′-Dideoxyadenosine, Lodenosine, in Rhesus Monkeys: Plasma and Cerebrospinal Fluid Pharmacokinetics and Urinary Disposition. Drug Metab Disp 1999; 27:1128–1132
Rouleau A, Garbarg M, Ligneau X, Mantion C, Lavie P, Lecomte J-M, Krause M, Stark H, Schunack W and Schwartz J-C. Bioavailability, Antinociceptive and Antiinflammatory Properties of BP 2-94, A Histamine H3 Receptor Agonist Prodrug. J Pharmacol Exp Ther 1997; 281:1085–1094
Rouquayrol M, Gaucher B, Greiner J, Aubertin A-M, Vierling P and Guedj R. Synthesis and Anti-HIV Activity of Glucose-Containing Prodrugs Derived from Saquinavir, Indinavir and Nelfinavir. Carbohydrate Res 2001; 336:161–180
Russell JW and Klunk LJ. Comparative Pharmacokinetics of New Anti-HIV agents: 2′,3′-Dideoxyadenosine and 2′,3′-Dideoxyinosine. Biochem Pharmacol 1989; 38:1385–1388
Saito Y, Buciak J, Yang J and Pardridge WM. Vector-Mediated Delivery of {sr1257#x007D;I-Labeled β-Amyloid Peptide A-β1-40 through the Blood-Brain Barrier and Binding to Alzheimer Disease Amyloid of the A-β1-40/Vector Complex. Proc Natl Acad Sci USA 1995; 92:10227–10231
Saletu B, Grunberger J and Linzmayer L. Acute and Subacute Central Nervous System Effects of Milacemide in Elderly People: Double-Blind Placebo Controlled Quantitative Electroencephalography and Psychometric Investigations. Arch Gerentol Geriat 1986; 5:165–182
Salituro FG, Tomlinson RC, Baron BM, Palfreyman MG, McDonald IA, Schmidt W, Wu H-Q, Guidetti P and Schwarcz R. Enzyme-Activated Antagonists of the Strychnine-Insensitive Glycine/NMDA Receptor. J Med Chem 1994; 37:334–336
Samtani MN, Schwab M, Nathanielsz PW and Jusko WJ. Stabilization and HPLC Analysis of Beztamethasone Sodium Phosphate in Plasma. J Pharm Sci 2004; 93:726–732
Sasaki S, Kanda T, Ishibashi N, Yamamoto F, Haradahira T, Okauchi T, Meda J, Suzuki K and Maeda M. 4,5,9,10-Tetrahydro-1,4-Ethanobenz [b]quinolizine as a Prodrug for its Quinolizinium Cation as a Ligand to the Open State of the TCP-Binding Site of NMDA Receptors. Bioorg Med Chem Lett 2001; 11:519–521
Sawchuk RJ and Yang Z. Investigation of Distribution, Transport and Uptake of Anti-HIV Drugs to the Central Nervous System. Adv Drug Deliv Rev 1999; 39:5–31
Schinkel AH and Jonker JW. Mammalian Drug Efflux Transporters of the ATP Binding Cassette (ABC) Family: An Overview. Adv Drug Deliv Rev 2003; 55:3–29
Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM and Borst P. Disruption of the Mouse MDR1a P-Glycoprotein Gene Leads to a Deficiency in the Blood-Brain Barrier and to Increased Sensitivity to Drugs. Cell 1994; 77:491–502
Schinkel AH, Wagenaar E, Mol CAAM and van Deemter L. P-Glycoprotein in the Blood-Brain Barrier of Mice Influences the Brain Penetration and Pharmacological Activity of Many Drugs. J Clin Invest 1996; 97:2517–2524
Schlienger N, Peyrottes S, Kassem T, Imbach J-L, Gosselin G, Aubertin A-M and Perigaud C. S-Acyl-2-Thioethyl Aryl Phosphotriester Derivatives as Mononucleotide Prodrugs. J Med Chem 2000; 43:4570–4574
Schrader WP, West CA and Strominger NL. Localization of Adenosine Deaminase and Adenosine Deaminase Complexing Protein in Rabbit Brain. J Histochem Cytochem 1987; 35:443–451
Schwartz BL, Hashtroudi S, Herting RL, Handerson H and Deutsch SI. Glycine Prodrug Facilitates Memory Retrieval in Humans. Neurology 1991; 41:1341–1343
Seetharaman S, Barrand MA, Maskell L and Scheper RJ. Multidrug Resistance-Related Transport Proteins in Isolated Human Brain Microvessels and in Cells Cultured from these Isolates. J Neurochem 1998; 70:1151–1159
Semba J, Curzon G and Patsalos PN. Antiepileptic Drug Pharmacokinetics and Neuropharmacokinetics in Individual Rats by Repetitive Withdrawal of Blood and Cerebrospinal Fluid: Milacemide. Br J Pharmacol 1993; 108:1117–1124
Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, Sorensen AG and Barbier N. A Phase 1-2 Clinical Trial of Gene Therapy for Recurrent Glioblastoma Multiforme by Tumour Transduction with Herpes Simplex Thymidine Kinase Gene followed by Ganciclovir. Hum Gene Ther 1999; 10:2325–2335
Shanmuganathan K, Koudriakova T, Nampalli S, Du J, Gallo JM, Schinazi RF and Chu CK. Enhanced Brain Delivery of an Anti-HIV Nucleoside 2′-F-ara-ddI by Xanthine Oxidase Mediated Biotransformation. J Med Chem 1994; 37:821–827
Shashoua VE, Jacob JN, Ridge R, Campbell A and Baldessarini RJ. γ-Aminobutyric Acid Esters. 1. Synthesis, Brain Uptake, and Pharmacological Studies of Aliphatic and Steroid Esters of γ-Aminobutyric Acid. J Med Chem 1984; 27:659–664
Sheha M, Al-Tayeb A, El-Sherief H and Farag H. New Carrier for Specific Delivery of Drugs to the Brain. Bioorg Med Chem 2003; 11:1865–1872
Shek E. Chemical Delivery Systems and Prodrugs of Anticonvulsive Drugs. Adv Drug Delivery Rev 1994; 14:227–241
Shirasaka T, Chokekijchai S, Yamada A, Gosselin G, Imbach J-L and Mitsuya H. Comparative Analysis of Anti-Human Immunodeficiency Virus Type 1 Activities of Dideoxynucleoside Analogs in Resting and Activated Peripheral Blood Mononuclear Cells. Antimicrob Agents Chemother 1995; 39:2555–2559
Shirasaka T, Murakami K, Ford H, Kelly JA, Yoshioka H, Kojima E, Aoki S, Broder S and Mitsuya H. Lipophilic Halogenated Congeners of 2′,3′-Dideoxypurine Nucleosides Active Against Human Immunodeficiency Virus In Vitro. Proc Natl Acad Sci USA 1990; 87:9426–9430
Singhal D and Anderson BD. Optimization of the Local Inhibition of Intestinal Adenosine Deaminase (ADA) by Erythro-9-(2-Hydroxy-3-Nonyl)adenine: Enhanced Oral Delivery of an ADA-Activated Prodrug for Anti-HIV Therapy. J Pharm Sci 1998; 87:578–585
Singhal D, Morgan ME and Anderson BD. The Role of Altered Metabolism in Dideoxynucleoside Pharmacokinetics. Studies of 2′-Fluoro-2′,3′-Dideoxyinosine and 2′-Fluoro-2′,3′-Dideoxyadenosine in Rats. Drug Metab Disp 1996; 24:1155–1161
Singhal D, Morgan ME and Anderson BD. Role of Brain Tissue Localized Purine Metabolizing Enzymes in the Central Nervous System Delivery of Anti-HIV Agents 2′-β-Fluoro-2′,3′-Dideoxyinosine and 2′-β-Fluoro-2′,3′-Dideoxyadenosine in Rats. Pharm Res 1997; 14:786–792
Singhal D, Ho NF and Anderson BD. Absorption and Intestinal Metabolism of Purine Dideoxynucleosides and an Adenosine Deaminase-Activated Prodrug of 2′,3′-Dideoxyinosine in the Mesenteric Vein Cannulated Rat Ileum. J Pharm Sci 1998; 87:569–577
Smith QR. Drug Delivery to Brain and the Role of Carrier-Mediated Transport. In: Drewes LR, and Betz AL. Frontiers in Cerebral Vascular Biology: Transport and Its Regulation. New York, Plenum Press; 1993:83–100
Solhonne B, Gros C, Pollard H and Schwartz JC. Major Localization of Aminopeptidase M in Rat Brain Microvessels. Neuroscience 1987; 22:225–232
Somogyi G, Buchwald P, Nomi D, Prokai L and Bodor N. Targeted Drug Delivery to the Brain via Phosphonate Derivatives II. Anionic Chemical Delivery System for Zidovudine (AZT). Int J Pharm 1998; 166:27–35
Somogyi G, Nishitani S, Nomi D, Buchwald P, Prokai L and Bodor N. Targeted Drug Delivery to the Brain via Phosphonate Derivatives. I. Design, Synthesis and Evaluation of an Anionic Chemical Delivery System for Testosterone. Int J Pharm 1997; 166:15–26
Starnes MC and Cheng Y-C. Cellular Metabolism of 2′,3′-Dideoxycytidine, a Compound Active Against Human Immunodeficiency Virus In Vitro. J Biol Chem 1987; 262:988–991
Stella VJ and Himmelstein KJ. Prodrugs and Site-Specific Delivery. J Med Chem 1980; 23:1275–1282
Stella VJ and Himmelstein KJ. Critique of Prodrugs and Site Specific Delivery. In: Bundgaard H, Hansen AB, and Kofod H. Optimization of Drug Delivery (Alfred Benzon Symposium). Copenhagen, Munksgaard; 1982:134–155
Stella V and Himmelstein KJ. Site-Specific Drug Delivery via Prodrugs. In: Bundgaard H. Design of Prodrugs. Amsterdam, Elsevier; 1985:177–198
Sugiyama Y, Kusuhara H and Suzuki H. Kinetic and Biochemical Analysis of Carrier-Mediated Efflux of Drugs through the Blood-Brain and Blood-Cerebrospinal Fluid Barriers: Importance in the Drug Delivery to the Brain. J Control Release 1999; 62:179–86
Sun H, Dai H, Shaik N and Elmquist WF. Drug Efflux Transporters in the CNS. Adv Drug Deliv Rev 2003; 55:83–105
Sunderland A, Mellow A, Cohen R, Lawlor B, Jill J, Newhouse P, Cohen M and Murphy D. Acute Effects of High-Dose Thyrotropin Releasing Hormone Infusions in Alzheimer’s Disease. Psychopharmacology 1989; 98:403–407
Takasawa K, Terasaki T, Suzuki H and Sugiyama Y. In Vivo Evidence for Carrier-Mediated Efflux Transport of 3′-Azido-3′-Deoxythymidine and 2′,3′-Dideoxyinosine across the Blood-Brain Barrier via a Probenecid-Sensitive Transport System. J Pharmacol Exp Ther 1997; 281:369–375
Tamai I and Tsuji A. Drug Delivery through the Blood-Brain Barrier. Adv Drug Deliv Rev 1996; 19:401–424
Tamai I and Tsuji A. Transporter-Mediated Permeation of Drugs across the Blood-Brain Barrier. J Pharm Sci 2000; 89:1371–1388
Tan X, Boudinot FD, Chu CK, Egron D, Perigaud C, Gosselin G and Imbach J-L. Pharmacokinetics of bis(t-butyl-SATE)-AZTMP, a Bispivaloylthioethyl Prodrug for Intracellular Delivery of Zidovudine Monophosphate, in Mice. Antivir Chem Chemother 2000; 11:203–212
Tapfer MK, Sebestyen L, Kurucz I, Horvath K, Szelenyi I and Bodor N. New Evidence for the Selective, Long-Lasting Central Effects of the Brain-Targeted Estradiol, Estredox. Pharmacol Biochem Behav 2004; 77:423–429
Terada LS, Willingham IR, Rosandich ME, Leff JA, Kindt GW and Repine JE. Generation of Superoxide Anion by Brain Endothelial Cell Xanthine Oxidase. J Cell Physiol 1991; 148:191–196
Tomlinson E. Theory and Practice of Site-Specific Drug Delivery. Adv Drug Del Rev 1987; 1:87–164
Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H and Sugiyama Y. A Physiologically Based Pharmacokinetic Analysis of Capecitabine, a Triple Prodrug of 5-FU in Humans: The Mechanism for Tumor-Selective Accumulation of 5-FU. Pharm Res 2001; 18:1190–1202
Tsuzuki N, Hama T, Kawada M, Hasui A, Konishi R, Shiwa S, Ochi Y, Futaki S and Kitagawa K. Adamantane as a Brain-Directed Drug Carrier for Poorly Absorbed Drug. 2. AZT Derivatives Conjugated with the 1-Adamantane Moiety. J Pharm Sci 1994; 83:481–484
Tuntland T, Ravasco RJ, Al-Habet S and Unadkat JD. Active Efflux of Zidovudine and 2′,3′-Dideoxyinosine out of the Cerebrospinal Fluid when Administered Alone and in Combination to the Macaca nemestrina. Pharm Res 1994; 11:312–317
Turner AJ, Hooper NM and Kenny AJ. Metabolism of Neuropeptides. In: Kenny AJ, and Turner AJ. Mammalian Ectoenzymes Amsterdam, Elsevier; 1987:221–241
Van der Weyden MB and Kelley WN. Human Adenosine Deaminase. Distribution and Properties. J Biol Chem 1976; 251:5448–5456
Van Dorsser W, Barris D, Cordi A and Roba J. Anticonvulsant Activity of Milacemide. Arch Int Pharmacodyn 1983; 266:239–249
Van Hoof VO, Deng JT and De Broe ME. How Do Plasma Membranes Reach the Circulation? Clin Chim Acta 1997; 266:23–31
Varasi M, Della Torre A, Heidempergher F, Pevarello P, Speciale C, guidetti P, Wells DR and Schwarcz R. Derivatives of Kynurenine as Inhibitors of Rat Brain Kynurenine Aminotransferase. Eur J Med Chem 1996; 31:11–21
Wada S, Tsuda M, Sekine T, Cha SH, Kimura M, Kanai Y and Endou H. Rat Multispecific Organic Anion Transporter 1 (rOAT1) Transports Zidovudine, Acyclovir, and Other Antiviral Nucleoside Analogs. J Pharmacol Exp Ther 2000; 294:844–849
Wade LA and Katzman R. Synthetic Amino Acids and the Nature of L-Dopa Transport at the Blood-Brain Barrier. J Neurochem 1975; 25:837–842
Wang H. Brain Delivery of Nipecotic Acid by the Administration of its Ester Prodrug via the Nasal Route. College of Pharmacy. Lexington, KY, University of Kentucky; 2003:172
Wang H, Hussain AA and Wedlund PJ. Nipecotic Acid: Systemic Availability and Brain Delivery After Nasal Administration of Nipecotic Acid and n-Butyl Nipecotate to Rats. Pharm Res 2005; 22:556–562
Wang Y and Sawchuk RJ. Zidovudine Transport in the Rabbit Brain during Intravenous and Intracerebroventricular Infusion. J Pharm Sci 1995; 84:871–876
Wang Y, Wei Y and Sawchuk RJ. Zidovudine Transport Within the Rabbit Brain during Intracerebroventricular Administration and the Effect of Probenecid. J Pharm Sci 1995; 86:1484–1490
Wang ZH, Samuels S, Gama Sosa MA and Kolodny EH. 5-Fluorocytosine-Mediated Apoptosis and DNA Damage in Glioma Cells Engineered to Express Cytosine Deaminase and their Enhancement with Interferon. J Neurooncol 1998; 36:219–229
Wang B, Nimkar K, Wang W, Zhang H, Shan D, Gudmundsson O, Gangwar S, Siahaan T and Borchardt RT. Synthesis and Evaluation of the Physicochemical Properties of Esterase-Sensitive Cyclic Prodrugs of Opioid Peptides Using Coumarinic Acid and Phenylpropionic Acid Linkers. J Pept Res 1999; 53:370–382
Wang ML, Yung WK, Royce ME, Schomer DF and Theriault RL. Capecitabine for 5-Fluorouracil-Resistant Brain Metastases from Breast Cancer. Am J Clin Oncol 2001; 24:421–424
Wang WJ, Tai C-K, Kasahara N and Chen TC. Highly Efficient and Tumor-Restricted Gene Transfer to Malignant Gliomas by Replication-Competent Retroviral Vectors. Hum Gene Ther 2003; 14:117–127
Wen Y-D, Remmel RP, Pham PT, Vince R and Zimmerman CL. Comparative Brain Exposure to (-)-Carbovir after (-)-Carbovir or (-)-6-Aminocarbovir Intravenous Infusion in Rats. Pharm Res 1995; 12:911–915
Witt KA, Huber JD, Egleton RD, Roberts MJ, Bentley MD, Guo L, Wei H, Yamamura HI and Davis TP. Pharmacodynamic and Pharmacokinetic Characterization of Poly(ethylene glycol) Conjugation to Met-Enkephalin Analog [D-Pen2, D-Pen5]-Enkephalin (DPDPE). J Pharmacol Exp Ther 2001; 298:848–856
Wong SL, Hedaya MA and Sawchuk RJ. Competitive Inhibition of Zidovudine Clearance by Probenecid during Continuous Coadministration. Pharm Res 1992; 9:228–235
Wu H-Q, Lee S-C, Scharfman HE and Schwarcz R. L-4-Chlorokynurenine Attenuates Kainate-Induced Seizures and Lesions in the Rat. Exp Neurol 2002; 177:222–232
Xiang T-X and Anderson BD. The Relationship between Permeant Size and Permeability in Lipid Bilayer Membranes. J Membr Biol 1994; 140:111–121
Xiang T-X and Anderson BD. Influence of Chain Ordering on the Selectivity of Dipalmitoylphosphatidylcholine Bilayer Membranes for Permeant Size and Shape. Biophys J 1998; 75:2658–2671
Yang JZ, Chen W and Borchardt RT. In Vitro Stability and In Vivo Pharmacokinetic Studies of a Model Opioid Peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its Cyclic Prodrugs. J Pharmacol Exp Ther 2002; 303:840–848
Yarbrough G. Thyrotropin Releasing Hormone and CNS Cholinergic Neurons. Life Sci 1983; 33:111–118
Yoshikawa T, Sakaeda T, Sugawara T, Hirano K and Stella VJ. A Novel Chemical Delivery System for Brain Targeting. Adv Drug Del Rev 1999; 36:255–275
Yu PH and Davis BA. Some Pharmacological Implications of MAO-Mediated Deamination of Branched Aliphatic Amines: 2-Propyl-1-Aminopentane and N-(2-Propylpentyl)glycinamide as Valproic Acid Precursors. J Neurol Trans Suppl 1990; 32:89–92
Yu PH and Davis BA. Simultaneous Delivery of Valproic Acid and Glycine to the Brain. Deamination of 2-Propylpentylglycinamide by Monoamine Oxidase B. Mol Chem Neuropath 1991; 15:37–49
Yu PH, Davis BA, Boulton AA and Zuo DM. Deamination of Aliphatic Amines by Type B Monoamine Oxidase and Semicarbazide-Sensitive Amine Oxidase; Pharmacological Implications. J Neural Transm Suppl 1994; 41:397–406
Zhang Y, Han H, Elmquist WF and Miller DW. Expression of Various Multidrug Resistance-Associated Protein (MRP) Homologues in Brain Microvessel Endothelial Cells. Brain Res 2000; 876:148–153
Zielke CL and Suelter CH. Purine, Purine Nucleoside, and Purine Nucleotide Aminohydrolases. In: Boyer PD. The Enzymes. London, Academic; 1971:47–78
Zlokovic BV. Cerebrovascular Permeability to Peptides: Manipulations of Transport Systems at the Blood-Brain Barrier. Pharm Res 1995; 12:1395–1406
Zlokovic BV, Lipovac MN, Begley DJ, Davson H and Rakic L. Slow Penetration of Thyrotropin-Releasing Hormone across the Blood-Brain Barrier of an In Situ Perfused Guinea Pig Brain. J Neurochem 1988; 51:252–257
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Anderson, B.D. (2007). Prodrug Approaches for Drug Delivery to the Brain. In: Stella, V.J., Borchardt, R.T., Hageman, M.J., Oliyai, R., Maag, H., Tilley, J.W. (eds) Prodrugs. Biotechnology: Pharmaceutical Aspects, vol V. Springer, New York, NY. https://doi.org/10.1007/978-0-387-49785-3_17
Download citation
DOI: https://doi.org/10.1007/978-0-387-49785-3_17
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-49782-2
Online ISBN: 978-0-387-49785-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)